Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from Lupin Limited ( (IN:LUPIN) ).
Lupin Limited has entered into a licensing and supply agreement, via its subsidiary Lupin Atlantis Holdings, with Spain-based Galenicum Health for finished injectable formulations of Semaglutide, a GLP-1 receptor agonist used in Type 2 diabetes and obesity management. Under the deal, Galenicum will develop, manufacture and supply the product, while Lupin will manage regulatory approvals and commercialization across 23 countries, including Canada, Europe, Southeast Asia and Latin America, sharpening Lupin’s push into the fast-growing GLP-1 market. The partnership is positioned as a strategic milestone that expands Lupin’s Semaglutide portfolio and leverages its existing commercial footprint to scale access to cost-effective diabetes and obesity treatments, while supporting Galenicum’s ambition to become a leading B2B GLP-1 supplier amid surging global demand for these therapies.
More about Lupin Limited
Lupin Limited is a global pharmaceutical company headquartered in Mumbai, India, with products distributed in over 100 markets. The company focuses on branded and generic formulations, complex generics, biotechnology products and active pharmaceutical ingredients, holding strong positions in key therapeutic areas such as diabetes and respiratory care in India, the U.S. and other major markets.
Average Trading Volume: 32,199
Technical Sentiment Signal: Strong Buy
Current Market Cap: 994.1B INR
See more data about LUPIN stock on TipRanks’ Stock Analysis page.